Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Assets (2016 - 2025)

Guided Therapeutics' Non-Current Assets history spans 16 years, with the latest figure at $104000.0 for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 49.51% year-over-year to $104000.0; the TTM value through Sep 2025 reached $104000.0, down 49.51%, while the annual FY2024 figure was $181000.0, 34.42% down from the prior year.
  • Non-Current Assets for Q3 2025 was $104000.0 at Guided Therapeutics, down from $129000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $446000.0 in Q1 2021 and bottomed at $104000.0 in Q3 2025.
  • The 5-year median for Non-Current Assets is $319000.0 (2023), against an average of $301578.9.
  • The largest annual shift saw Non-Current Assets skyrocketed 570.97% in 2021 before it crashed 49.51% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $403000.0 in 2021, then fell by 10.17% to $362000.0 in 2022, then decreased by 23.76% to $276000.0 in 2023, then plummeted by 34.42% to $181000.0 in 2024, then tumbled by 42.54% to $104000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Non-Current Assets are $104000.0 (Q3 2025), $129000.0 (Q2 2025), and $156000.0 (Q1 2025).